Jose Luis Guerrero-Naranjo, MD (Mexico City, Mexico), Hugo Quiroz-Mercado, MD (Mexico City, Mexico), Virgilio Morales- Canton, MD (Mexico City, Mexico), Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City,Mexico), Adriana Solis-Vivanco, MD (Mexico City, Mexico), Elizabeth Reyna-Castelan, MD (Mexico City, Mexico), Maura Abraham, MD (Mexico City, Mexico), Juan Manuel Jimenez-Sierra, MD (Mexico City, Mexico), Myrian Hernandez, MD (Mexico City, Mexico),Orlando Ustariz-Gonzalez, MD (Mexico City, Mexico)


Evaluate visual results and changes in macular thickness measured by optical coherence tomography (OCT) in patients diagnosed with macular edema secondary to vein occlusions, treated with intravitreal Bevacizumab.


Case serie, prospective and experimental pilot study. 15 eyes diagnosed with vein occlusion, 11 with branch vein occlusions (BVO) and 4 with central retinal vein occlusion (CRVO), were treated with 0.1ml (1.25mg) intravitreal bevacizumab and followed up during 3 months with best-corrected visual acuity, OCT, and fluorescein angiography.


Best-corrected visual acuity mean at baseline was 20/400 which improve to 20/100 during the first month and 20/60 on the third month follow-up (p=0.001, Wilcoxon Signed Rank Test). Baseline macular thickness mean was 334.60+ 145.28 μm which decreased to 223.40+ 110.89 μm (p=0.007, Wilcoxon Signed Rank Test) after the first month. There were no ocular or systemic adverse events identified.


Intravitreal bevacizumab is a safe and effective therapy for patients with vein occlusions. The three month follow-up showed a statistically significant improvement in visual acuity, OCT, and angiographic outcomes.